Clinical trial · Interventional
Ifosfamide and Doxorubicin, Radiation Therapy, and/or Surgery in Treating Young Patients With Localized Soft Tissue Sarcoma
Localized Non-Rhabdomyosarcoma Soft Tissue Sarcomas
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Drugs used in chemotherapy, such as ifosfamide and doxorubicin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving combination chemotherapy with or without radiation therapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. Giving radiation therapy after surgery may kill any tumor cells that remain after surgery. PURPOSE: This phase III trial is studying how well giving ifosfamide and doxorubicin, radiation therapy, and/or surgery works in treating young patients with localized soft tissue sarcoma.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Childhood Malignant Fibrous Histiocytoma of Bone | Childhood Undifferentiated High Grade Pleomorphic Sarcoma of Bone | ALIAS | 0.90 |
| Sarcoma | Sarcoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (6)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| adjuvant therapy | Procedure | — | UNRESOLVED |
| conventional surgery | Procedure | — | UNRESOLVED |
| doxorubicin hydrochloride | Drug | Doxorubicin | ALIAS |
| ifosfamide | Drug | Ifosfamide | ALIAS |
| neoadjuvant therapy | Procedure | — | UNRESOLVED |
| radiation therapy | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (5)
- measure
- Event-free survival
- measure
- Local relapse-free survival
- measure
- Metastases-free survival
- measure
- Overall survival
- measure
- Response rate (complete response, very good partial response [PR], PR, minor PR, and stable disease)
Eligibility
Eligibility (as posted)
- Sex
- All
- Maximum age
- 20 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS:
* Histologically confirmed synovial sarcoma or adult-type soft-tissue sarcoma
* Adult-type soft tissue sarcoma includes any of the following:
* Fibrosarcoma (adult-type)
* No infantile fibrosarcoma
* Malignant peripheral nerve sheath tumor
* Malignant schwannoma
* Neurofibrosarcoma
* Epithelioid sarcoma
* Leiomyosarcoma
* Clear cell sarcoma
* Liposarcoma
* Alveolar soft-part sarcoma
* Malignant fibrous histiocytoma
* Hemangiopericytoma
* Angiosarcoma
* Dermatofibrosarcoma protuberans
* Mesenchymal chondrosarcoma
* No borderline tumors (e.g., hemangioendothelioma)
* No small round cell tumors (e.g., extraosseous Ewing's sarcoma/primitive neuroectodermal tumor or desmoplastic small round cell tumor)
* Post-irradiation soft-part sarcomas allowed
* Diagnostic surgery performed within the past 8 weeks (for patients who require adjuvant chemotherapy)
* No evidence of metastatic disease
* Involved locoregional lymph nodes are allowed
PATIENT CHARACTERISTICS:
* No prior malignancy
* No pre-existing illness precluding study treatment\*
* Normal renal function (nephrotoxicity grade 0-1)\*
* No history of cardiac disease\*
* Normal shortening fraction (\> 28%)\*
* Ejection fraction \> 47%\* NOTE: \* For patients who require adjuvant chemotherapy
PRIOR CONCURRENT THERAPY:
* No prior cancer treatment except primary surgeryReferences
Publications (0)
Data not yet available